Incyte Corp

1 de jul. de 2026, 21:01 UTC

Incyte Corp shares are higher in after-market trading, reflecting a notable increase as they approach the upper end of their one-month range.

30 de jun. de 2026, 23:01 UTC

Incyte Corp shares are higher in after-market trading, maintaining an upward trend despite broader market declines, particularly in the tech sector.

29 de jun. de 2026, 23:16 UTC

Incyte Corp shares are higher in after-market trading following positive results from the Phase 2b trial of EVO756 for chronic spontaneous urticaria.

26 de jun. de 2026, 23:51 UTC

Incyte Corp shares are higher in after-market trading following a positive recommendation for Opzelura® cream from the European Medicines Agency's Committee for Medicinal Products.

25 de jun. de 2026, 23:51 UTC

Incyte Corp shares are higher in after-market hours, recovering from an earlier session low. Broader market performance remains mixed amid varying tech stock results.

24 de jun. de 2026, 20:02 UTC

HC Wainwright reiterated its Buy rating on Incyte Corp with a $140 price target, contributing to the stock's advance amid positive social media sentiment.

23 de jun. de 2026, 19:46 UTC

Incyte Corp shares are higher today, reflecting a cumulative gain since Monday. The stock has rebounded from an earlier session pullback amid broader market pressures.

22 de jun. de 2026, 20:02 UTC

Incyte Corp's stock is higher after Japan approved Minjuvi for lymphoma treatment. BMO upgraded the company to Market Perform and raised its price target to $94.

18 de jun. de 2026, 22:16 UTC

Incyte Corp shares are trading higher in after-market hours. No specific news was identified to explain this movement amid a broader market uptrend.

17 de jun. de 2026, 23:46 UTC

Incyte Corp shares are lower in after-market trading following significant volatility. Broader market trends may be affecting investor sentiment amid stronger U.S. retail sales.

16 de jun. de 2026, 19:22 UTC

Incyte shares are lower despite positive phase II study results for zilurgisertib. The FDA has begun Priority Review of the New Drug Application.

15 de jun. de 2026, 14:23 UTC

Incyte Corp's stock is lower as analysts raise concerns over clinical data despite promising Phase 3 trial results for tafasitamab.

12 de jun. de 2026, 22:02 UTC

Incyte Corp shares are lower in after-market hours, continuing a trend of unusual weakness since Friday's close, with no specific news identified.

11 de jun. de 2026, 22:02 UTC

Incyte Corp shares are lower in after-market hours, despite being above their 20-day moving average and three consecutive sessions of higher closes.

10 de jun. de 2026, 21:02 UTC

Incyte shares rise in after-market trading on Guggenheim target increase.

9 de jun. de 2026, 20:02 UTC

Incyte Corp gains as HC Wainwright raises price target to $140 and the company announces a $1.25 billion acquisition of Vega Therapeutics.

8 de jun. de 2026, 19:42 UTC

Incyte Corp shares are lower after announcing a $1.25 billion acquisition of Vega Therapeutics, which will impact upcoming financial results significantly.

5 de jun. de 2026, 22:51 UTC

Incyte Corp shares are higher in after-market trading, reflecting positive market sentiment following stronger-than-expected U.S. job growth data.

4 de jun. de 2026, 20:01 UTC

Incyte shares rise as results from the Phase 2 PROGRESS study will be presented at ENDO 2026, supporting the FDA's Priority Review of its application.

3 de jun. de 2026, 20:02 UTC

Incyte Corp shares are higher today, breaking a recent trend. The ADP Employment Report showed stronger-than-expected job growth, influencing broader market sentiment.

2 de jun. de 2026, 23:06 UTC

Incyte Corp. shares are trading roughly flat in after-market hours, following a session that saw a peak gain earlier.

1 de jun. de 2026, 19:36 UTC

Incyte Corp's stock is lower after the Phase 3 frontMIND trial results raised safety concerns despite showing efficacy in treating high-risk lymphoma patients.

29 de mai. de 2026, 23:46 UTC

Incyte Corp shares are lower in after-market hours, reflecting a slight decline since Friday's close without any specific news to explain the movement.

28 de mai. de 2026, 20:06 UTC

Incyte Corp shares are higher today, recovering from earlier losses amid modest overall market performance. No specific company news was identified to explain the movement.

27 de mai. de 2026, 23:06 UTC

Incyte Corp. shares remain roughly flat in after-market trading, with no specific news identified and movement within a narrow range since Wednesday's close.

26 de mai. de 2026, 20:06 UTC

Incyte Corp. shares are lower today, reflecting a decline since Friday's close amid broader market focus on upcoming economic data releases.

21 de mai. de 2026, 19:26 UTC

HC Wainwright & Co. reiterated a Buy rating on Incyte Corp with a $135 price target, contributing to the stock's upward movement since Wednesday.

20 de mai. de 2026, 23:56 UTC

Incyte Corp shares are lower in after-market trading, amid tightening global financial conditions and rising policy rates. The broader market has shown recent strength.

19 de mai. de 2026, 19:36 UTC

Incyte Corp partners with Edison Scientific to use AI in drug discovery. Shares are trading higher, reflecting broader gains in the Biotechnology sector.